313,559 Shares in Dyne Therapeutics, Inc. $DYN Bought by University of Wisconsin Foundation

University of Wisconsin Foundation bought a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN) during the 2nd quarter, HoldingsChannel reports. The fund bought 313,559 shares of the company’s stock, valued at approximately $6,964,000. Dyne Therapeutics makes up 5.5% of University of Wisconsin Foundation’s investment portfolio, making the stock its 9th largest position.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Hilton Head Capital Partners LLC purchased a new stake in Dyne Therapeutics during the 1st quarter valued at $26,000. Strs Ohio purchased a new position in shares of Dyne Therapeutics in the fourth quarter valued at about $51,000. Allworth Financial LP purchased a new position in shares of Dyne Therapeutics in the second quarter valued at about $62,000. Aster Capital Management DIFC Ltd bought a new position in shares of Dyne Therapeutics during the fourth quarter valued at about $84,000. Finally, Steward Partners Investment Advisory LLC raised its stake in shares of Dyne Therapeutics by 102.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after acquiring an additional 2,465 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, Director Jason P. Rhodes sold 2,160,516 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $25.00, for a total value of $54,012,900.00. Following the completion of the transaction, the director owned 428,946 shares in the company, valued at approximately $10,723,650. This represents a 83.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Erick Lucera sold 2,362 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $20.37, for a total value of $48,113.94. Following the transaction, the chief financial officer directly owned 121,563 shares of the company’s stock, valued at $2,476,238.31. This represents a 1.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 4,139,196 shares of company stock worth $99,449,852 over the last 90 days. 9.46% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on DYN shares. Wall Street Zen cut Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. TD Cowen assumed coverage on Dyne Therapeutics in a research report on Friday, June 26th. They set a “buy” rating for the company. Cantor Fitzgerald started coverage on Dyne Therapeutics in a report on Thursday, July 23rd. They issued an “overweight” rating for the company. Sanford C. Bernstein lifted their price objective on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a research report on Monday, August 17th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Dyne Therapeutics has an average rating of “Moderate Buy” and an average price target of $34.42.

Dyne Therapeutics Stock Performance

Dyne Therapeutics stock opened at $25.99 on Tuesday. The stock’s 50 day simple moving average is $23.83 and its two-hundred day simple moving average is $19.83. The company has a debt-to-equity ratio of 0.28, a quick ratio of 12.02 and a current ratio of 12.02. The stock has a market cap of $4.85 billion, a price-to-earnings ratio of -7.80 and a beta of 1.07. Dyne Therapeutics, Inc. has a fifty-two week low of $11.92 and a fifty-two week high of $27.31.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). As a group, analysts expect that Dyne Therapeutics, Inc. will post -3.47 earnings per share for the current fiscal year.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.